BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
Number Cited Articles
1
Franziska Wewering, Florent Jouy, Dirk K. Wissenbach, Scarlett Gebauer, Matthias Blüher, Rolf Gebhardt, Ralph Pirow, Martin von Bergen, Stefan Kalkhof, Andreas Luch, Sebastian Zellmer. Characterization of chemical-induced sterile inflammation in vitro: application of the model compound ketoconazole in a human hepatic co-culture systemArchives of Toxicology 2017; 91(2): 799 doi: 10.1007/s00204-016-1686-y
2
Emanuel Raschi, Elisabetta Poluzzi, Fabrizio De Ponti. Comment on: “Pharmacokinetics in Patients with Chronic Liver Disease and Hepatic Safety of Incretin-Based Therapies for the Management of Type 2 Diabetes Mellitus”Clinical Pharmacokinetics 2015; 54(4): 447 doi: 10.1007/s40262-015-0248-4
3
Frank P. Tverdek, Diamantis Kofteridis, Dimitrios P. Kontoyiannis. Antifungal agents and liver toxicity: a complex interactionExpert Review of Anti-infective Therapy 2016; 14(8): 765 doi: 10.1080/14787210.2016.1199272
4
Viktorija O. Barr, Elizabeth G. Zdyb, Michael Postelnick. The Clinical Significance of Azole Antifungals’ Effects on the Liver and Transaminase LevelsCurrent Fungal Infection Reports 2015; 9(3): 190 doi: 10.1007/s12281-015-0226-1
5
Patrizia Haegler, Lorenz Joerin, Stephan Krähenbühl, Jamal Bouitbir. Hepatocellular Toxicity of Imidazole and Triazole Antimycotic AgentsToxicological Sciences 2017; 157(1): 183 doi: 10.1093/toxsci/kfx029
6
Felix Bongomin, Isabel Rodriguez-Goncer, Carol Lorden, Akaninyene Otu, Rohit Bazaz. Late-onset isavuconazole-induced liver injuryMedical Mycology Case Reports 2018; 22: 11 doi: 10.1016/j.mmcr.2018.07.006
7
David J. Greenblatt. The Pharmacovigilance SyndromeJournal of Clinical Psychopharmacology 2015; : 1 doi: 10.1097/JCP.0000000000000367
8
Gemma Hayes, Lilyann Novak-Frazer. Chronic Pulmonary Aspergillosis—Where Are We? and Where Are We Going?Journal of Fungi 2016; 2(2): 18 doi: 10.3390/jof2020018
9
Lydia L. Benitez, Peggy L. Carver. Adverse Effects Associated with Long-Term Administration of Azole Antifungal AgentsDrugs 2019; 79(8): 833 doi: 10.1007/s40265-019-01127-8
10
Emanuel Raschi, Fabrizio De Ponti. Drug- and herb-induced liver injury: Progress, current challenges and emerging signals of post-marketing riskWorld Journal of Hepatology 2015; 7(13): 1761-1771 doi: 10.4254/wjh.v7.i13.1761
11
B.S. Navarro, M.E. Auler, R.L.O. Dos Santos, L. da Silva Ruiz, D.C. Nascimento, P.A.N. Felippe, C. Domaneschi, D. Moreira, F.A. Baroni, M.F.C. Pires, C.R. Paula. Antifungal sensitivity and species of yeasts in oral mucosa of street mixed-breed dogsJournal de Mycologie Médicale 2020; : 101010 doi: 10.1016/j.mycmed.2020.101010
12
Robert John Fontana, Elizabeth Theresa Cirulli, Jiezhun Gu, David Kleiner, David Ostrov, Elizabeth Phillips, Ryan Schutte, Huiman Barnhart, Naga Chalasani, Paul Brent Watkins, Jay H. Hoofnagle. The role of HLA-A*33:01 in patients with cholestatic hepatitis attributed to terbinafineJournal of Hepatology 2018; 69(6): 1317 doi: 10.1016/j.jhep.2018.08.004
13
Tim Bühler, Michael Medinger, Jamal Bouitbir, Stephan Krähenbühl, Anne Leuppi-Taegtmeyer. Hepatotoxicity Due to Azole Antimycotic Agents in a HLA B*35:02-Positive PatientFrontiers in Pharmacology 2019; 10 doi: 10.3389/fphar.2019.00645
14
Qiang Shi, Xi Yang, James J. Greenhaw, Alec Thomas Salminen, Gary M. Russotti, William F. Salminen. Drug-Induced Liver Injury in Children: Clinical Observations, Animal Models, and Regulatory StatusInternational Journal of Toxicology 2017; 36(5): 365 doi: 10.1177/1091581817721675
15
Aditya K. Gupta, Kelly A. Foley, Sarah G. Versteeg. New Antifungal Agents and New Formulations Against DermatophytesMycopathologia 2017; 182(1-2): 127 doi: 10.1007/s11046-016-0045-0
16
Andreas H Groll, Bart J A Rijnders, Thomas J Walsh, Jill Adler-Moore, Russell E Lewis, Roger J M Brüggemann. Clinical Pharmacokinetics, Pharmacodynamics, Safety and Efficacy of Liposomal Amphotericin BClinical Infectious Diseases 2019; 68(Supplement_4): S260 doi: 10.1093/cid/ciz076
17
M.A. Gupta, B. Vujcic, A.D. Sheridan, A.K. Gupta. Reduced risk of suicidal behaviours associated with the treatment of hidradenitis suppurativa with tumour necrosis factor alpha antagonists: results from the US FDA Adverse Events Reporting System pharmacovigilance database Journal of the European Academy of Dermatology and Venereology 2020; 34(7): 1564 doi: 10.1111/jdv.16224
18
Noémi Outeiro, Nicolas Hohmann, Gerd Mikus. No Increased Risk of Ketoconazole Toxicity in Drug-Drug Interaction StudiesThe Journal of Clinical Pharmacology 2016; 56(10): 1203 doi: 10.1002/jcph.795
19
Peymaan S. Banankhah, Kyle A. Garnick, David J. Greenblatt. Ketoconazole-Associated Liver Injury in Drug-Drug Interaction Studies in Healthy VolunteersThe Journal of Clinical Pharmacology 2016; 56(10): 1196 doi: 10.1002/jcph.711
20
Nikolaos Spernovasilis, Diamantis Kofteridis. Pre-Existing Liver Disease and Toxicity of AntifungalsJournal of Fungi 2018; 4(4): 133 doi: 10.3390/jof4040133
21
Zainab M. Mahdi, Uta Synal-Hermanns, Aylin Yoker, Kaspar P. Locher, Bruno Stieger. Role of Multidrug Resistance Protein 3 in Antifungal-Induced CholestasisMolecular Pharmacology 2016; 90(1): 23 doi: 10.1124/mol.116.103390
22
Emanuel Raschi, Elisabetta Poluzzi, Ariola Koci, Francesco Salvo, Antoine Pariente, Maurizio Biselli, Ugo Moretti, Nicholas Moore, Fabrizio De Ponti. Liver injury with novel oral anticoagulants: assessing post-marketing reports in the US Food and Drug Administration adverse event reporting systemBritish Journal of Clinical Pharmacology 2015; 80(2): 285 doi: 10.1111/bcp.12611
23
Jackson Thomas, Gregory M. Peterson, Julia K. Christenson, Sam Kosari, Kavya E. Baby. Antifungal Drug Use for OnychomycosisAmerican Journal of Therapeutics 2019; 26(3): e388 doi: 10.1097/MJT.0000000000000696
24
Ioannis Kyriakidis, Athanasios Tragiannidis, Silke Munchen, Andreas H. Groll. Clinical hepatotoxicity associated with antifungal agentsExpert Opinion on Drug Safety 2016; : 1 doi: 10.1080/14740338.2017.1270264
25
Aditya K. Gupta, Rachel R. Mays, Sarah G. Versteeg, Neil H. Shear, Vincent Piguet. Update on current approaches to diagnosis and treatment of onychomycosisExpert Review of Anti-infective Therapy 2018; 16(12): 929 doi: 10.1080/14787210.2018.1544891
26
David J. Greenblatt. Evidence-based choice of ritonavir as index CYP3A inhibitor in drug-drug interaction studiesThe Journal of Clinical Pharmacology 2016; 56(2): 152 doi: 10.1002/jcph.609
27
David J. Greenblatt, Gerd Mikus. Ketoconazole and Liver Injury: A Five-Year UpdateClinical Pharmacology in Drug Development 2019; 8(1): 6 doi: 10.1002/cpdd.652
28
A.K. Gupta, J. Carviel, M.A. Gupta, N.H. Shear. Assessing dutasteride-associated sexual dysfunction using the U.S. Food and Drug Administration Adverse Event Reporting SystemJournal of the European Academy of Dermatology and Venereology 2018; 32(8): 1373 doi: 10.1111/jdv.14728
29
Aditya K. Gupta, Sarah G. Versteeg, Neil H. Shear. Confirmatory Testing Prior to Initiating Onychomycosis Therapy Is Cost-EffectiveJournal of Cutaneous Medicine and Surgery 2018; 22(2): 129 doi: 10.1177/1203475417733461
30
Rachel Gallant, Phillip Bonney, Leigh Peek, Zhongxin Yu, David Crawford. Voriconazole-induced hepatotoxicity following the administration of PEG-asparaginase: Case reportPediatric Blood & Cancer 2017; 64(6): e26293 doi: 10.1002/pbc.26293
31
Ippazio Cosimo Antonazzo, Elisabetta Poluzzi, Emanuele Forcesi, Trond Riise, Kjetil Bjornevik, Elisa Baldin, Luigi Muratori, Fabrizio De Ponti, Emanuel Raschi. Liver injury with drugs used for multiple sclerosis: A contemporary analysis of the FDA Adverse Event Reporting SystemMultiple Sclerosis Journal 2019; 25(12): 1633 doi: 10.1177/1352458518799598
32
Bhavana Rajbanshi, Liangliang Shen, Miao Jiang, Qingyu Gao, Xin Huang, Jiaoyang Ma, Jihong Wang, Yang Hu, Hongli Lv, Xiao Wu, Jingjun Zhao. Comparative Study of Traditional Ablative CO2 Laser-Assisted Topical Antifungal with only Topical Antifungal for Treating Onychomycosis: A Multicenter StudyClinical Drug Investigation 2020; 40(6): 575 doi: 10.1007/s40261-020-00914-6
33
David J. Greenblatt, Jerold S. Harmatz. Ritonavir is the best alternative to ketoconazole as an index inhibitor of cytochrome P450-3A in drug-drug interaction studiesBritish Journal of Clinical Pharmacology 2015; 80(3): 342 doi: 10.1111/bcp.12668
34
Maria Clara Padovani de Souza, Andrezza Gouvêa dos Santos, Adriano Max Moreira Reis. Adverse Drug Reactions in Patients Receiving Systemic Antifungal Therapy at a High-Complexity HospitalThe Journal of Clinical Pharmacology 2016; 56(12): 1507 doi: 10.1002/jcph.772
35
A.K. Gupta, J. Carviel, M.A. MacLeod, N. Shear. Assessing finasteride-associated sexual dysfunction using the FAERS databaseJournal of the European Academy of Dermatology and Venereology 2017; 31(6): 1069 doi: 10.1111/jdv.14223
36
Miriam T. Levine, Pranatharthi H. Chandrasekar. Adverse effects of voriconazole: Over a decade of useClinical Transplantation 2016; 30(11): 1377 doi: 10.1111/ctr.12834
37
Harshad Devarbhavi. Acute Liver Failure Induced by Anti-infectious Drugs: Causes and ManagementCurrent Hepatology Reports 2017; 16(4): 276 doi: 10.1007/s11901-017-0367-5
38
Romeo-Gabriel Mihăilă. Voriconazole and the liverWorld Journal of Hepatology 2015; 7(14): 1828-1833 doi: 10.4254/wjh.v7.i14.1828
39
Vincent Lo Re, Dena M. Carbonari, James D. Lewis, Kimberly A. Forde, David S. Goldberg, K. Rajender Reddy, Kevin Haynes, Jason A. Roy, Daohang Sha, Amy R. Marks, Jennifer L. Schneider, Brian L. Strom, Douglas A. Corley. Oral Azole Antifungal Medications and Risk of Acute Liver Injury, Overall and by Chronic Liver Disease StatusThe American Journal of Medicine 2016; 129(3): 283 doi: 10.1016/j.amjmed.2015.10.029